The drug is already approved to treat other certain forms of breast cancer, but not for reducing the chances of cancer recurring. Despite progress in the treatment of breast cancer, about 30% with a common subtype of early breast cancer are at risk of their cancer returning, according to Eli Lilly. …read more
Source:: Yahoo Finance
